Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eye Diseases AND Retinal Neovascularization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    56 result(s) found for: Eye Diseases AND Retinal Neovascularization. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-001640-38 Sponsor Protocol Number: ATTRACT Start Date*: 2014-08-08
    Sponsor Name:CHU DE POITIERS
    Full Title: Efficacy of Aflibercept (Eylea®) on Type 3 choroidal neovascularization.
    Medical condition: Retinal diseases (type 3 choroidal neovascularization)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001781-15 Sponsor Protocol Number: IOBA-04-2012 Start Date*: 2012-07-31
    Sponsor Name:IOBA, Universidad de Valladolid
    Full Title: Initial protocol setting for the treatment of choroidal neovascularization associated to myopia magna with intravitreal bevacizumab: 3 vs 1 (BENEMCOR.es study)
    Medical condition: choroidal neovascularization associated to myopia magna
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005056-15 Sponsor Protocol Number: AGO/2013/012 Start Date*: 2014-03-21
    Sponsor Name:UZ Gent
    Full Title: Longterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.
    Medical condition: Choroidal neovascularisation and chronic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10054467 Macular edema LLT
    21.1 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001085-10 Sponsor Protocol Number: CRFB002AGB17 Start Date*: 2014-09-08
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravit...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020441-27 Sponsor Protocol Number: CORaLa Start Date*: 2011-02-23
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion A randomized, controlled interventional phase 2b (proof of concept) study of ...
    Medical condition: macular edema secondary to non-ischemic central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10054467 Macular edema LLT
    14.0 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005081-19 Sponsor Protocol Number: 1 Start Date*: 2014-07-10
    Sponsor Name:HOSPICES CIVILS DELYON
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of idiopathic choroidal neovascularization in young subjects: the INTUITION study
    Medical condition: idiopathic choroidal neovascularization
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014612-34 Sponsor Protocol Number: CRFB002APT02T Start Date*: 2011-09-12
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, multicenter, open-label study to evaluate the safety and efficacy of intravitreal ranibizumab in patients with subfoveal or juxtafoveal choroidal neovascularization (CNV) secondary to ...
    Medical condition: Patients with subfoveal or juxtafoveal choroidal neovascularization secondary to other causes than Age-related Macular Degeneration and Pathological Myopia (angioid streaks, pseudohistoplasmosis, i...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002431-15 Sponsor Protocol Number: CRFB002ADE23 Start Date*: 2013-10-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness sta...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002384-15 Sponsor Protocol Number: 3.0 Start Date*: 2014-10-23
    Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie
    Full Title: Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV
    Medical condition: Exsudative Maculopathies
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    17.0 10015919 - Eye disorders 10052501 Detachment of retinal pigment epithelium PT
    17.0 10015919 - Eye disorders 10069125 Retinal angiomatous proliferation LLT
    17.0 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010973-19 Sponsor Protocol Number: 14130 Start Date*: 2009-09-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondar...
    Medical condition: Maculare edema secondary to Central Retinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10054467 Macular edema LLT
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) LV (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004844-35 Sponsor Protocol Number: TG-MV-005 Start Date*: 2009-07-01
    Sponsor Name:ThromboGenics NV
    Full Title: A randomized, sham-injection controlled, double-masked, multicenter trial of microplasmin intravitreal injection for treatment of exudative age-related macular degeneration (AMD).
    Medical condition: Patients with exudative AMD with focal vitreomacular adhesion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    9.1 10051065 Vitreomacular traction syndrome LLT
    9.1 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003640-23 Sponsor Protocol Number: ECR-RET-2013-05 Start Date*: 2014-01-13
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP ...
    Medical condition: Patients with type I or type II diabetes mellitus and high risk diabetic retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005417-38 Sponsor Protocol Number: CRFB002G2301 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) LV (Completed) PT (Completed) HU (Completed) CZ (Completed) ES (Completed) LT (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005439-10 Sponsor Protocol Number: RabOCT Start Date*: 2013-08-30
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retin...
    Medical condition: macular edema secondary to branch retinal vein occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10054467 Macular edema LLT
    18.1 100000004853 10038906 Retinal vein branch occlusion LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003334-33 Sponsor Protocol Number: CRFB002FIT01 Start Date*: 2013-12-16
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 12-month, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal ...
    Medical condition: Choroidal neovascularization secondary to pathologic myopia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000681-42 Sponsor Protocol Number: CoRaLa_II Start Date*: 2020-08-24
    Sponsor Name:Justus-Liebig University Gießen
    Full Title: Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion
    Medical condition: Macular edema due to central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10054467 Macular edema LLT
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001421-55 Sponsor Protocol Number: CRFB002GFR02 Start Date*: 2013-06-13
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases.
    Medical condition: Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Ret...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10047060 Retina, choroid and vitreous haemorrhages and vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004486-13 Sponsor Protocol Number: QL1205-002 Start Date*: 2019-04-18
    Sponsor Name:Qilu Pharmaceutical Co., Ltd.
    Full Title: A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration
    Medical condition: Subjects With Wet (neovascular) Age-related Macular Degeneration (wAMD), aged ≥50 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) LV (Completed) PL (Completed) BG (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000487-11 Sponsor Protocol Number: CRFB002D2201 Start Date*: 2005-09-30
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the...
    Medical condition: Male and female patients >18 years of age with either type 1 or type 2 diabetes mellitus with stable HbA1c levels between 6.5 and 10% and diabetic macular edema with center involvement in at least ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002626-23 Sponsor Protocol Number: CRFB002A2411 Start Date*: 2013-11-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen,...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) BE (Completed) DE (Completed) SK (Completed) GB (Completed) HU (Completed) PT (Completed) DK (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 20 08:51:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA